Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, successfully raised $289 million in its US initial public offering (IPO). Shares priced at the top of the marketed range, signaling strong investor confidence. The San Carlos, California-based biotech firm sold 17 million shares for $17 each, an increase from its initial offer of 12.5 million shares marketed at $15 to $17. This robust demand led to an upsized, top-tier pricing.
The successful capital raise provides Attovia significant financial resources to advance its clinical pipeline. At the IPO price, Attovia commands a market value of $731.5 million based on outstanding shares, establishing it as a notable new public market entrant.
Attovia’s development strategy utilizes a technology platform and patents licensed from Alamar Biosciences Inc., a company specializing in medical devices for studying proteins and disease detection. Alamar Biosciences established Attovia as a separate entity in 2023 and remains an investor. Alamar itself raised $219.9 million in its own IPO, with shares climbing over 59% since its April debut. Prior to its public listing, Attovia secured $255.8 million as of March 31 from investors including an affiliate of Goldman Sachs Group Inc., Deep Track Capital, Frazier Life Sciences, and venBio, according to regulatory filings.
Pipeline and Market Context
The company’s pipeline features two key drug candidates. One, aimed at interleukin-31, has completed dosing in a Phase 1 trial. A second candidate, targeting interleukin-13, is expected to commence trials in the first half of next year. These programs highlight Attovia’s commitment to developing novel therapies for complex immune-mediated conditions.
Attovia’s successful IPO reflects a broader trend of strong performance among biotechnology and pharmaceutical companies entering the public market this year. New listings have been robust, with several firms demonstrating significant post-debut gains. Veradermics Inc., focused on pattern hair loss, saw shares surge 531% since its February debut. Blood disorder specialist Hemab Therapeutics Inc. recorded a 158% gain following its IPO in May, illustrating a receptive market for innovative drug developers.
Underwriting and Trading Debut
The IPO was jointly led by a syndicate including Morgan Stanley, Leerink Partners, Citigroup Inc., and Royal Bank of Canada. Attovia’s shares are anticipated to begin trading Wednesday on the Nasdaq Global Market under the symbol ATTO, marking its official entry into the public equity landscape.
The $289 million capital infusion provides Attovia Therapeutics substantial resources to accelerate its clinical development programs and further its mission of addressing high unmet needs in immune system diseases. Strong investor reception, evidenced by top-of-range pricing and increased deal size, strategically positions Attovia for sustained growth and innovation as it transitions to a publicly traded entity, aiming to bring transformative therapies to patients.
